Switching to another drug would have been beneficial for second-line therapy of GIST because sunitinib is also a substrate of CYP3A4 and thus a victim of CYP3A4 induction by carbamazepine. The gene discussed is CYP3A4; the disease is gastrointestinal stromal tumor.